Latest Period
Q1 2026
Security Snapshot
Context Therapeutics Inc. - Common Stock (CNTX) Institutional Ownership
CUSIP: 21077P108
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
57
Shares (Excl. Options)
73,709,454
Price
$2.62
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- CNTX on Nasdaq
- Shares outstanding
- 91,741,639
- Price per share
- $2.51
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 73,709,454
- Total reported value
- $191,817,599
- % of total 13F portfolios
- 0%
- Share change
- +8,864,401
- Value change
- +$28,460,414
- Number of holders
- 57
- Price from insider filings
- $2.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CNTX - Context Therapeutics Inc. - Common Stock is tracked under CUSIP 21077P108.
- 57 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 42 to 57 between Q4 2025 and Q1 2026.
- Reported value moved from $95,840,638 to $191,817,599.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 57 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 21077P108?
CUSIP 21077P108 identifies CNTX - Context Therapeutics Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 21077P108:
Significant Owners of Context Therapeutics Inc. - Common Stock (CNTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MPM BioImpact LLC | 12% | -30% | $15,698,705 | -$5,918,942 | 10,679,391 | -27% | MPM BioImpact LLC | 31 Dec 2025 |
| Avidity Partners Management LP | 8.7% | -12% | $21,753,357 | -$2,352,163 | 8,302,808 | -9.8% | Avidity Partners Management LP | 31 Mar 2026 |
| Deep Track Capital, LP | 8.3% | $7,419,355 | 7,419,355 | Deep Track Capital, LP | 31 Mar 2025 | |||
| Soleus Capital Master Fund, L.P. | 7.6% | +48% | $18,243,429 | +$5,729,267 | 6,963,141 | +46% | Soleus Capital Master Fund, L.P. | 31 Mar 2026 |
| Octagon Capital Advisors LP | 5.7% | $13,755,000 | 5,250,000 | Octagon Capital Advisors LP | 31 Mar 2026 | |||
| Blue Owl Capital Holdings LP | 5.5% | -37% | $13,333,219 | -$3,324,552 | 5,089,015 | -20% | Blue Owl Capital Holdings LP | 31 Mar 2026 |
| FRANKLIN RESOURCES INC | 4.5% | -16% | $4,003,380 | 4,003,380 | 0% | Franklin Resources, Inc. | 31 Mar 2025 | |
| GREAT POINT PARTNERS LLC | 2.4% | -53% | $5,864,860 | -$6,406,463 | 2,238,496 | -52% | Great Point Partners, LLC | 31 Mar 2026 |
| Lehr Martin A. | 2.1% | $1,595,742 | 1,595,742 | Martin Lehr | 31 Dec 2024 |
As of 31 Mar 2026, 57 institutional investors reported holding 73,709,454 shares of Context Therapeutics Inc. - Common Stock (CNTX). This represents 80% of the company’s total 91,741,639 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Context Therapeutics Inc. - Common Stock (CNTX) together control 78% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MPM BIOIMPACT LLC | 12% | 10,679,391 | 0% | 2.2% | $27,980,004 |
| Nextech Invest, Ltd. | 8.1% | 7,419,355 | 0% | 1.4% | $19,438,710 |
| Deep Track Capital, LP | 8.1% | 7,419,355 | 0% | 0.4% | $19,438,710 |
| Soleus Capital Management, L.P. | 7.6% | 6,963,141 | 0.74% | $18,243,429 | |
| Octagon Capital Advisors LP | 5.7% | 5,250,000 | 1.5% | $13,755,000 | |
| Blue Owl Capital Holdings LP | 5.5% | 5,089,015 | -32% | 3.6% | $13,333,219 |
| Avidity Partners Management LP | 5.4% | 4,998,267 | -9.2% | 2.9% | $11,795,910 |
| FRANKLIN RESOURCES INC | 4.1% | 3,803,338 | -5% | 0% | $9,964,746 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 3,431,953 | 0% | 0% | $8,991,717 |
| MARSHALL WACE, LLP | 3.2% | 2,948,441 | +14% | 0.01% | $7,724,916 |
| TCG Crossover Management, LLC | 2.9% | 2,682,696 | 0.2% | $7,028,664 | |
| GREAT POINT PARTNERS LLC | 2.4% | 2,238,496 | -52% | 1.4% | $5,864,860 |
| MILLENNIUM MANAGEMENT LLC | 1.6% | 1,424,374 | -45% | 0% | $3,731,860 |
| Squadron Capital Management LLC | 1.2% | 1,100,000 | 1.2% | $2,882,000 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.2% | 1,093,894 | 0% | $2,866,002 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.1% | 1,000,000 | 0% | $2,620,000 | |
| Sio Capital Management, LLC | 1% | 917,922 | -32% | 0.35% | $2,404,956 |
| BlackRock, Inc. | 0.92% | 846,696 | -0.16% | 0% | $2,218,344 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.66% | 603,767 | -0.77% | 0% | $1,582,701 |
| Cormorant Asset Management, LP | 0.58% | 529,550 | 0.07% | $1,387,421 | |
| JANE STREET GROUP, LLC | 0.48% | 436,931 | 0% | $1,144,760 | |
| VANGUARD FIDUCIARY TRUST CO | 0.37% | 341,344 | 0% | 0% | $894,321 |
| GOLDMAN SACHS GROUP INC | 0.31% | 287,299 | 0% | $752,723 | |
| Woodline Partners LP | 0.27% | 250,088 | 0% | $655,231 | |
| STATE STREET CORP | 0.25% | 233,507 | +41% | 0% | $611,788 |
Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 73,709,454 | $191,817,599 | +$28,460,414 | $2.62 | 57 |
| 2025 Q4 | 65,197,080 | $95,840,638 | -$5,288,639 | $1.47 | 42 |
| 2025 Q3 | 68,966,266 | $66,815,968 | +$689,909 | $0.97 | 37 |
| 2025 Q2 | 68,619,580 | $44,959,003 | -$1,721,044 | $0.66 | 39 |
| 2025 Q1 | 71,405,968 | $43,712,940 | -$1,099,517 | $0.61 | 42 |
| 2024 Q4 | 72,797,034 | $76,436,064 | +$15,827,475 | $1.05 | 52 |
| 2024 Q3 | 56,682,696 | $111,154,599 | -$854,175 | $1.96 | 42 |
| 2024 Q2 | 57,034,586 | $114,325,460 | +$107,182,399 | $2.00 | 34 |
| 2024 Q1 | 3,935,132 | $5,430,813 | +$524,452 | $1.38 | 25 |
| 2023 Q4 | 3,558,639 | $4,020,714 | +$1,102,318 | $1.13 | 24 |
| 2023 Q3 | 2,578,656 | $3,893,359 | +$507,040 | $1.51 | 23 |
| 2023 Q2 | 2,239,166 | $3,582,021 | +$1,631,639 | $1.60 | 22 |
| 2023 Q1 | 1,276,355 | $717,889 | -$1,585,759 | $0.56 | 20 |
| 2022 Q4 | 3,883,345 | $2,545,096 | -$383,818 | $0.65 | 23 |
| 2022 Q3 | 4,130,839 | $4,587,000 | +$1,461,710 | $1.11 | 21 |
| 2022 Q2 | 2,747,803 | $5,761,000 | -$388,653 | $2.12 | 17 |
| 2022 Q1 | 2,904,420 | $6,302,000 | -$2,229,327 | $2.17 | 12 |
| 2021 Q4 | 3,549,370 | $9,441,000 | +$8,486,000 | $2.66 | 16 |